These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1038 related articles for article (PubMed ID: 28810142)
1. Control of Metastasis by NK Cells. López-Soto A; Gonzalez S; Smyth MJ; Galluzzi L Cancer Cell; 2017 Aug; 32(2):135-154. PubMed ID: 28810142 [TBL] [Abstract][Full Text] [Related]
2. Bench to bedside: NK cells and control of metastasis. Krasnova Y; Putz EM; Smyth MJ; Souza-Fonseca-Guimaraes F Clin Immunol; 2017 Apr; 177():50-59. PubMed ID: 26476139 [TBL] [Abstract][Full Text] [Related]
3. NK cells-directed therapies target circulating tumor cells and metastasis. Dianat-Moghadam H; Mahari A; Heidarifard M; Parnianfard N; Pourmousavi-Kh L; Rahbarghazi R; Amoozgar Z Cancer Lett; 2021 Jan; 497():41-53. PubMed ID: 32987138 [TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive cells in tumor immune escape and metastasis. Liu Y; Cao X J Mol Med (Berl); 2016 May; 94(5):509-22. PubMed ID: 26689709 [TBL] [Abstract][Full Text] [Related]
8. NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy? Cantoni C; Huergo-Zapico L; Parodi M; Pedrazzi M; Mingari MC; Moretta A; Sparatore B; Gonzalez S; Olive D; Bottino C; Castriconi R; Vitale M J Immunol Res; 2016; 2016():4684268. PubMed ID: 27294158 [TBL] [Abstract][Full Text] [Related]
10. Innate and acquired immune surveillance in the postdissemination phase of metastasis. Gonzalez H; Robles I; Werb Z FEBS J; 2018 Feb; 285(4):654-664. PubMed ID: 29131550 [TBL] [Abstract][Full Text] [Related]
11. NK cells to cure cancer. Di Vito C; Mikulak J; Zaghi E; Pesce S; Marcenaro E; Mavilio D Semin Immunol; 2019 Feb; 41():101272. PubMed ID: 31085114 [TBL] [Abstract][Full Text] [Related]
12. Platelet-Mediated Protection of Cancer Cells From Immune Surveillance - Possible Implications for Cancer Immunotherapy. Schmied L; Höglund P; Meinke S Front Immunol; 2021; 12():640578. PubMed ID: 33777033 [TBL] [Abstract][Full Text] [Related]
13. Mechanism of tumor cells escaping from immune surveillance of NK cells. Ge Z; Wu S; Zhang Z; Ding S Immunopharmacol Immunotoxicol; 2020 Jun; 42(3):187-198. PubMed ID: 32223464 [TBL] [Abstract][Full Text] [Related]
14. Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity. Pasero C; Gravis G; Guerin M; Granjeaud S; Thomassin-Piana J; Rocchi P; Paciencia-Gros M; Poizat F; Bentobji M; Azario-Cheillan F; Walz J; Salem N; Brunelle S; Moretta A; Olive D Cancer Res; 2016 Apr; 76(8):2153-65. PubMed ID: 27197252 [TBL] [Abstract][Full Text] [Related]
15. Metastases in immune-mediated dormancy: a new opportunity for targeting cancer. Romero I; Garrido F; Garcia-Lora AM Cancer Res; 2014 Dec; 74(23):6750-7. PubMed ID: 25411345 [TBL] [Abstract][Full Text] [Related]
16. Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. Mohme M; Riethdorf S; Pantel K Nat Rev Clin Oncol; 2017 Mar; 14(3):155-167. PubMed ID: 27644321 [TBL] [Abstract][Full Text] [Related]
17. Ly49 family receptors are required for cancer immunosurveillance mediated by natural killer cells. Tu MM; Mahmoud AB; Wight A; Mottashed A; Bélanger S; Rahim MM; Abou-Samra E; Makrigiannis AP Cancer Res; 2014 Jul; 74(14):3684-94. PubMed ID: 24802191 [TBL] [Abstract][Full Text] [Related]
18. NK cells in the tumor microenvironment: Prognostic and theranostic impact. Recent advances and trends. Russick J; Torset C; Hemery E; Cremer I Semin Immunol; 2020 Apr; 48():101407. PubMed ID: 32900565 [TBL] [Abstract][Full Text] [Related]
19. Remodeled tumor immune microenvironment (TIME) parade via natural killer cells reprogramming in breast cancer. Elanany MM; Mostafa D; Hamdy NM Life Sci; 2023 Oct; 330():121997. PubMed ID: 37536617 [TBL] [Abstract][Full Text] [Related]